Hong Ren

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Stephen L. Chan, Shanzhi Gu et al. · The Lancet · 2023 · 590 citations

First-line Therapy, Hepatology, International Phase 3 +8

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Shilong Yang, Yan Li, Lianpan Dai et al. · The Lancet Infectious Diseases · 2021 · 451 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +7

Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound

Jie Wang, Tao Shen, Xiangbo Huang et al. · Journal of Hepatology · 2016 · 434 citations · Full text

Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)

Jinlin Hou, Guiqiang Wang, Fu‐Sheng Wang et al. · Journal of Clinical and Translational Hepatology · 2017 · 275 citations · Full text

Hepatitis D, Infectious Disease Prevention, Hepatology +8

Liver-infiltrating CD11b−CD27− NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression

Qiongfang Zhang, Wenwei Yin, Yang Xia et al. · Cellular and Molecular Immunology · 2016 · 168 citations · Full text